Clinical and Laboratory Outcomes of the Solid Cancer Patients Reinfected with SARS-CoV-2

Ünsal, Oktay; Yazıcı, Ozan; Özdemir, Nuriye; Çubukçu, Erdem; Ocak, Birol; Üner, Aytuğ; Özet, Ahmet

doi:10.2217/fon-2021-0621

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the remaining 47 studies under full-text reading, 28 studies were excluded. Eventually, 19 articles were included in this meta-analysis and systematic review based on the inclusion criteria [ 10 , 11 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ] The literature retrieval flow chart is shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis

Deng

Liu

et al. 2023

IJERPH

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection has brought new challenges to the global prevention and control of coronavirus disease 2019 (COVID-19) pandemic; however, current studies suggest that there is still great uncertainty about the risk of severe COVID-19 and poor outcomes after SARS-CoV-2 reinfection. Random-effects inverse-variance models were used to evaluate the pooled prevalence (PP) and its 95% confidence interval (CI) of severity, outcomes and symptoms of reinfection. Random-effects were used to estimate the pooled odds ratios (OR) and its 95%CI of severity and outcomes between reinfections and primary infections. Nineteen studies involving a total of 34,375 cases of SARS-CoV-2 reinfection and 5,264,720 cases of SARS-CoV-2 primary infection were included in this meta-analysis. Among those SARS-CoV-2 reinfection cases, 41.77% (95%CI, 19.23–64.31%) were asymptomatic, and 51.83% (95%CI, 23.90–79.76%) were symptomatic, only 0.58% (95%CI, 0.031–1.14%) manifested as severe illness, and 0.04% (95%CI, 0.009–0.078%) manifested as critical illness. The PPs for SARS-CoV-2 reinfection-related hospitalization, admission to ICU, and death were, respectively, 15.48% (95%CI, 11.98–18.97%), 3.58% (95%CI, 0.39–6.77%), 2.96% (95%CI, 1.25–4.67%). Compared with SARS-CoV-2 primary infection cases, reinfection cases were more likely to present with mild illness (OR = 7.01, 95%CI, 5.83–8.44), and the risk of severe illness was reduced by 86% (OR = 0.14, 95%CI, 0.11–0.16). Primary infection provided some protection against reinfection and reduces the risk of symptomatic infection and severe illness. Reinfection did not contribute to extra risk of hospitalization, ICU, or death. It is suggested to scientifically understand the risk of reinfection of SARS-CoV-2, strengthen public health education, maintain healthy habits, and reduce the risk of reinfection.

show abstract

Section: Resultsmentioning

confidence: 99%

Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis

Deng

Liu

et al. 2023

IJERPH

View full text Add to dashboard Cite

show abstract

“…Our study identified a small percentage of patients (6.7%) in the treatment group with low neutralization values after the second vaccination dose compared to the non‐cancer control group. These patients would probably be at greater risk of infection, reinfection, and complications in case of infections [ 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors

et al. 2022

View full text Add to dashboard Cite

Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post‐vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA‐1237 vaccine, and were compared with a group of 26 non‐cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS‐CoV‐2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non‐cancer groups were significant in individuals without previous SARS‐CoV‐2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non‐cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS‐CoV‐2 vaccination programs.

show abstract

“…Finally the rate of following up in intensive care unit after COVID-19 infection was high patients with malignancy in the studies. [19] While Zhang et al showed this rate as 21.6%, Yang et al found this rate as 20%. [20,21] In our study, we found that the rate of intensive care unit management of patients with after COVID-19 vaccine was %12.6 and this finding demonstrated that COVID-19 vaccination could reduce the need of intensive care unit management.…”

Section: Discussionmentioning

confidence: 97%

COVID-19 Infection After Different Combinations of Vaccines in Patients with Solid Tumors

Unsal

2023

EJMI

View full text Add to dashboard Cite

T he Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has revealed to the development of vaccines based on various technologies such as BNT162b2 (Pfizer-BioNTech), CoronaVac (Sinovac Biotech), AZD1222 (Oxford/AstraZeneca), mRNA-1273 (Moderna), Ad26.COV2.S (Johnson & Jonhson), Sputnik V (Gamaleya), as SARS-CoV-2 infection is associated with significant mortality and morbidity. BNT162b2, a nucleoside-modified mRNA vaccine and CoronoVac inactivated SARS-CoV-2 vaccine are the mostly used vaccines in Turkey. [1,2] The patients with cancer are more vulnerable to serious Coronavirus Disease 2019-related (COVID-19) complica-tions and mortality due to factors such as advanced age, comorbitidies, immunosupression, poor health status, so that vaccination against COVID-19 has been widely encouraged in patients with cancer, regardless of the origin of disease, the type of treatment. [3,4] The efficacy and optimal timing of vaccination in relation to cycles of chemotherapy for an effective immunity in this patient spectrum remains an important focus of the studies which do not provide satisfactory information unlike in general population. Studies using anti-SARS-CoV-2 spike protein immunoglobulin G titres, demonstrated an insufficient response after vaccination in patients with cancer. Becerril-Objectives: This study aimed to evaluate the cancer patients with COVID-19 infection after receiving different combinations of the COVID-19 vaccines for effective vaccination strategies. Methods: Eighty nine point thirty three percent (89.33%) of 3832 with solid malignancy were received at least 2 doses of COVID-19 vaccine. A total of 167 cancer patients with COVID-19 infection at least 28 days after the last dose of CO-VID-19 vaccine were included in the study. Results: Forty one point nine percent (41.9%) of the study population were received two doses of CoronaVac vaccine, 21.5% of the them; two doses of CoronaVac vaccine and one dose of BNT162b2 vaccine, 18.6% of them; two doses of BNT162b2 vaccine and 18% of them; three doses of CoronaVac vaccine. The median day from the last dose of vaccination to infection was significantly longer in patients with receiving cytotoxic chemotherapy than others (p=0.02). The requirement of oxygen support was high numerically in patients received the last of cytotoxic chemotherapy in 1-14 days prior to COVID-19 infection (23%). Conclusion:This study outlined the similar efficacy of the different combinations of COVID-19 vaccine by evaluating the clinical parameters in patients with solid malignancy.

show abstract

Clinical and Laboratory Outcomes of the Solid Cancer Patients Reinfected with SARS-CoV-2

Cited by 3 publications

References 34 publications

Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis

Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors

COVID-19 Infection After Different Combinations of Vaccines in Patients with Solid Tumors

Contact Info

Product

Resources

About